Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13754262 | 0.85 | PTGS2 (0.67) | PTGS2HTR2AHTR2CHTR2BCA2 | |
| SCHEMBL22817375 | 0.82 | CYP4F2 (0.41) | HTR2AHTR2CHTR2BCA2TAAR1 | |
| SCHEMBL13226752 | 0.82 | PTGS2 (0.57) | PTGS2HTR2AHTR2CHTR2BCA2 | |
| SCHEMBL6886890 | 0.80 | HDAC1 (0.37) | PTGS2TAAR1LMNA | |
| SCHEMBL12560288 | 0.79 | PTGS2 (0.59) | PTGS2HTR2AHTR2CHTR2BCA2 | |
| SCHEMBL16502336 | 0.78 | PTGS2 (0.53) | PTGS2TAAR1KDM4EALDH1A1LMNA | |
| SCHEMBL12763628 | 0.77 | PTGS2 (0.52) | PTGS2HTR2AHTR2CHTR2BCA2 | |
| SCHEMBL12763938 | 0.74 | PTGS2 (0.48) | PTGS2HTR2AHTR2CHTR2BKDM4E | |
| SCHEMBL13086666 | 0.74 | TUBB1 (0.39) | TUBB1LMNAMAPK1 | |
| SCHEMBL17864550 | 0.74 | ACHE (0.52) | KDM4ETUBB1ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590130-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-17 | — | — | US | disclosed |
| US-20190100520-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100520-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | PTGS2 901/4885HTR2A 3597/4885HTR2C 2236/4885 |
| US-10590130-B2 | Chemical compounds | MKI67, CCNI, MCL1 | PTGS2 901/4885HTR2A 3597/4885HTR2C 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.